Coccidioides immitis spherule
Brand names: Spherusol · Active ingredient: Coccidioides Immitis Spherule
In short: Spherusol ® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol ® is approved for use in individuals 18-64 years of age.
What is Coccidioides immitis spherule used for?
Spherusol
® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to
Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol
® is approved for use in individuals 18-64 years of age.
The use of Spherusol
® to detect delayed-type hypersensitivity responses in a general population with unknown exposure to
C. immitis has not been evaluated.
Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol
®.
Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol
®.
⚠ Boxed warning (FDA's strongest warning)
The expected response to Spherusol
® is a local area of inflammation at the site of the skin test. The reaction is usually dime to quarter size reaching maximum diameter between 24 and 48 hours. Larger accelerated reactions can occur, which may require treatment with local cold compresses and anti-inflammatory medication.
(
2.3,
6.1)
Systemic reactions can occur with skin test antigens and in certain individuals these reactions may be life-threatening or cause death. Emergency measures and personnel trained in their use should be immediately available. Patients should be observed for at least 20 minutes following the administration of a skin test.
(
6.2)
Spherusol
® should never be given intravenously. (
5)
To report SUSPECTED ADVERSE REACTIONS, contact Nielsen BioSciences, Inc. at (855) 855-1212 or MEDWATCH, Food and Drug Administration (FDA), 5600 Fishers Lane, Rockville, MD 20852-9782. Telephone: (800) 332-1088 or
www.vaers.hhs.gov. (
6.2)
Coccidioides immitis spherule dosage
2.1 Preparation for Administration
Spherusol
® is a clear, colorless sterile solution for intradermal administration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If any of these conditions exists, the skin test antigen should not be administered.
2.2 Administration:
Spherusol
® is administered as a 0.1 mL dose by intradermal injection to the volar surface of the forearm using a tuberculin syringe (0.5 or 1.0 mL) and a ½ inch 26-27 gauge needle. The needle should be inserted bevel side up in the skin at a 15-20 degree angle. Intradermal injection of 0.1 mL Spherusol
® will result in a bleb 5-10 mm in diameter at the injection site.
2.3 Skin Test Assessment
The injection site should be assessed for induration at 48 hours (±4 hours) following administration. The response to the skin test should be measured by taking the mean of the orthogonal diameters of the area of induration. A mean induration of ≥ 5 mm is considered a positive delayed-type hypersensitivity response to Spherusol
®.
Repeat administration of Spherusol
® has not been evaluated.
How to take Coccidioides immitis spherule — instructions & advice from the label
Patients should be:
Informed of the potential benefits and risks of skin testing with Spherusol
®.
Instructed to report any adverse events to their healthcare provider.
Warnings & precautions
Do not take this medicine if: A severe allergic reaction (e.g., anaphylaxis) to Spherusol
®, or any component of Spherusol
® or other coccidioidin products is a contraindication to administration.
5.1 Prevention and Management of Acute Hypersensitivity Reactions
Prior to administration, the healthcare provider should review the medical history for possible skin test sensitivity and previous skin test related adverse reactions to assess the risks and benefits. Immediate hypersensitivity, to include severe systemic reactions, may occur following administration of skin test antigens. Medications and equipment to manage possible anaphylactic reactions should be available for immediate use. Patients should be observed for a minimum of 30 minutes following administration to assess for adverse reactions.
5.2 Patients on Beta Blockers
Patients receiving beta blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis.
5.3 Immunosuppression
Any condition or agent that impairs or attenuates delayed-type hypersensitivity reactions, including infections and use of immunosuppressive drugs, can potentially cause a false negative reaction to Spherusol
®.
Coccidioides immitis spherule side effects
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a skin test antigen cannot be directly compared to rates in the clinical trials of another skin test antigen, and may not reflect the rates observed in practice. As with any skin test antigen, there is the possibility that broad use of Spherusol
® could reveal adverse reactions not observed in clinical trials.
In a double-blinded placebo-controlled clinical trial conducted in areas of the U.S. endemic for
C. immitis (Bakersfield, CA and Tucson, AZ), 54 adults (23-64 years of age) with a history of pulmonary coccidioidomycosis of at least 45 days duration, diagnosed by clinical findings, radiography and serological and/or mycological evidence of the disease, received a single dose of Spherusol
® concomitantly with two licensed skin test extracts (Candin
® and Trichophyton) and two controls (product diluent [thimerosal ≤0.0001%] and saline). Each intradermal injection of 0.1 mL of reagent was given at pre-determined sites on the right and left forearms. Solicited local adverse reactions and systemic adverse events occurring within 7 days after injection were recorded by study subjects via diary card. These events were also recorded on case report forms (CRFs) by study personnel during clinical visits 48 hours and 7 days following injections. Diary cards and CRFs did not record solicited local reactions by specific site. …
Drug interactions
7.1 Corticosteroids and Immunosuppressives
Corticosteroids and Immunosuppressive agents may suppress the response to the skin test. Pharmacologic doses of corticosteroids may suppress the response to skin test antigens after two weeks of therapy. The mechanism of suppression is thought to involve a decrease in monocytes and lymphocytes, particularly T-cells. The normal DTH response usually returns to pre-treatment levels within several weeks after steroid therapy is discontinued.
(5) The use of Spherusol
® has not been evaluated during or following the use of corticosteroids or immunosuppressive agents.
7.2 Antifungal Medications
It is not known if concurrent treatment with antifungal medications interferes with delayed-type hypersensitivity responses to Spherusol
® in patients with a history of pulmonary coccidioidomycosis.
About this medicine
Spherusol
® is a sterile aqueous solution of extracts of
C. immitis spherules. The multi-dose vial contains 0.9% sodium chloride and 0.014% sodium borate with 0.4% phenol as a preservative. Residual thimerosal from the manufacturing process is present at a concentration of ≤0.0001% (<0.05 mcg mercury/0.1 mL dose). Each 0.1 mL dose contains 1.27 mcg of spherule-derived antigen.
The potency of each lot of Spherusol
® is determined in sensitized guinea pigs.
How it works: 12.1 Mechanism of Action In individuals with a history of pulmonary coccidioidomycosis Spherusol ® is thought to elicit a cellular immune reaction to C. immitis, as evidenced by a delayed-type hypersensitivity (DTH) response to Coccidioidin (1,2,3,4). The general mechanism of the DTH response is based on the interaction of antigen with CD 4 and CD 8 lymphocytes followed by the secretion of interleukins and other lymphokines from macrophage cells.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 77108624-4771-4886-a3e2-b2625c444d1b. Read the full official label on DailyMed.